Browse the evidence

A lower-dose, theory-based maintenance intervention (Standard) achieves resistance training adherence rates statistically equivalent to a higher-dose, tailored intervention (SCT) in older adults with prediabetes, while being significantly less expensive.

To maintain resistance training long-term, you do not need expensive, highly personalized coaching. A simple, low-cost approach involving basic education, a barrier/strategy manual, and minimal check-ins (e.g., twice over six months) can be just as effective as intensive, tailored support. Focus on establishing the habit and self-regulation skills early, then reduce the intensity of external support to a sustainable, low-cost level.

Bariatric surgery (RYGB, SG, BPD/DS) is the most effective long-term treatment for severe obesity, achieving 15-30% total weight loss, but carries significant risks of micronutrient deficiencies and lean body mass loss due to anatomical malabsorption.

Bariatric surgery is the most effective long-term weight loss option for severe obesity, but it is not a simple fix. It requires lifelong commitment to high-dose nutritional supplementation and regular medical monitoring to prevent serious deficiencies in iron, B12, and calcium, as well as loss of muscle mass. The procedure works through complex metabolic changes, not just stomach size reduction.

Bariatric surgery significantly increases the risk of bone loss and fractures, particularly in malabsorptive procedures, due to reduced calcium absorption and secondary hyperparathyroidism, which is not fully mitigated by standard calcium and vitamin D supplementation.

If you have bariatric surgery, especially a malabsorptive type like gastric bypass, your risk of bone fractures increases significantly. Standard calcium and vitamin D supplements often fail to prevent this bone loss. You need specialized, long-term bone health monitoring beyond standard care.

Anti-obesity medications (AOMs) such as GLP-1 receptor agonists do not render lifestyle-based treatments obsolete; rather, they act synergistically by addressing physiological barriers to weight loss, allowing behavioral interventions to focus on optimizing body composition and long-term health maintenance.

Do not stop your lifestyle efforts when starting medication. Use the medication to manage hunger and physiological resistance, then redirect that energy into building fitness, muscle mass, and healthy eating habits. The medication handles the biology; you handle the lifestyle optimization for long-term health.

A ketogenic diet tends to cause greater losses in body weight, fat mass, and fat-free mass compared to higher-carbohydrate diets, likely due to differences in calorie and protein intake and fluid shifts rather than the diet itself being inherently superior for fat loss.

If you want to lose fat, a ketogenic diet can help you lose weight, but it is not inherently better than other diets. The greater weight loss seen is likely due to eating fewer calories and losing water weight. Ensure you are consuming enough protein to preserve muscle mass, regardless of the diet you choose.

A ketogenic diet has similar effects on maximal strength or strength gains from resistance training compared to a higher-carbohydrate diet, although a minority of studies show superior effects for non-ketogenic diets.

If your goal is to build strength, you can do so on a ketogenic diet. Studies show similar strength gains compared to high-carbohydrate diets. However, some studies suggest non-ketogenic diets might be slightly superior, so monitor your progress and adjust if needed.

High body mass index (BMI) and visceral adiposity are strong, independent risk factors for the development and progression of chronic kidney disease (CKD), end-stage renal disease (ESRD), and obesity-related glomerulopathy (ORG).

Maintaining a healthy weight is critical for kidney health. High BMI and visceral fat directly damage kidneys through increased pressure and hormonal imbalances, leading to chronic kidney disease. While weight loss in advanced kidney disease is complex, preventing obesity is the most effective way to protect your kidneys from long-term damage.

Obesity is associated with a significantly increased risk of kidney cancer, with a 5 kg/m2 higher BMI associated with a 25% higher risk of kidney cancers.

Obesity increases your risk of developing kidney cancer. Maintaining a healthy weight can help reduce this risk.

Insulin resistance (IR) and the resulting hyperinsulinemia constitute the primary shared pathogenic mechanism linking metabolic syndrome, obesity, and type 2 diabetes (T2DM), driving cardiovascular disease (CVD) risk through prothrombotic effects, endothelial dysfunction, and atherogenic dyslipidemia.

Focus on improving insulin sensitivity through lifestyle changes rather than assuming disease is inevitable due to family history. Managing insulin levels via diet and activity can mitigate the risk of cardiovascular complications associated with metabolic syndrome and obesity.

Metabolomic profiling (metabotyping) reveals that metabolic syndrome, obesity, T2DM, and CVDs share common metabolic signatures and pathways, suggesting that dietary interventions and pharmacologic treatments can target these shared traits.

Understanding that these diseases share metabolic roots allows for integrated treatment strategies, such as dietary changes that address insulin resistance and inflammation, benefiting multiple conditions simultaneously.

Gut microbiota composition determines individual variability in postprandial glycemic responses to standardized meals, enabling prediction of glucose spikes via machine learning models trained on metagenomic data.

Your gut bacteria uniquely determine how your blood sugar reacts to food. This is why one person might spike after a meal while another doesn't. Personalized nutrition strategies based on your microbiome can help manage glucose levels more effectively than generic advice.

Increased circulating levels of branched-chain amino acids (BCAAs) and imidazole propionate, linked to gut microbiota function, are associated with insulin resistance and higher risk of type 2 diabetes.

High levels of certain metabolites like BCAAs and imidazole propionate in your blood are linked to insulin resistance. These are partly produced by your gut bacteria, suggesting that a balanced diet supporting a healthy microbiome is important for metabolic health.

Educational documentaries can significantly increase intentions to reduce meat consumption, but these increased intentions do not translate into reduced actual consumption.

You can watch a documentary and genuinely *want* to eat less meat, but that desire alone won't change your diet. The study shows that while intentions go up, actual eating habits stay the same. To bridge this gap, you need more than just motivation; you need a plan, recipes, and environmental support to turn that intention into action.

Newer GLP-1RAs achieve average weight loss of 15% or greater, but a substantial number of patients fail to achieve even 5% weight loss, and weight loss is lower in older adults, males, and those with type 2 diabetes.

If you are on a GLP-1RA and not losing weight, you are not alone. Older adults, men, and those with type 2 diabetes often lose less weight on average. Discuss this with your doctor to see if lifestyle adjustments or other strategies can help improve your response.

Obesity and metabolic syndrome significantly impair the anabolic response (lean mass and strength gains) to resistance exercise and protein supplementation in older adults, creating anabolic resistance that limits muscle recovery during weight management.

If you are older and have excess body fat or metabolic issues, standard resistance training and protein intake will be less effective at building muscle than they are for leaner individuals. This is due to 'anabolic resistance' caused by inflammation and insulin resistance. To overcome this, you likely need higher-quality protein sources (like whey/casein blends with creatine and omega-3s) rather than just any protein, and you must prioritize metabolic health improvements alongside training.

Higher doses of tirzepatide (10-15 mg), younger age, and female sex are associated with a longer time to reach a weight plateau compared to lower doses (5 mg), older age, and male sex.

If you are on tirzepatide and your weight loss slows down significantly (plateau), do not panic or assume the drug has stopped working. This is a normal physiological adaptation. The study shows that people on higher doses, younger people, and women tend to reach this plateau later because they lose more total weight. Focus on maintaining the negative energy balance rather than chasing rapid scale changes. If you are on a lower dose (5mg), you may plateau sooner than those on 10-15mg, but this does not mean the treatment is ineffective.

Four weeks of daily arachidonic acid (ARA) supplementation (1.5 g/day) does not enhance the acute muscle protein synthesis (MPS) or anabolic signaling response to resistance exercise in trained men, but it does stimulate ribosome biogenesis 48 hours post-exercise.

If you are a trained man taking 1.5g of Arachidonic Acid daily, do not expect it to increase your muscle growth immediately after your workout. The study shows it has no effect on the first 4 hours of recovery. However, it might help your muscles build more protein-making machinery (ribosomes) two days after your workout, which could support long-term adaptation. Focus on your training and protein intake for immediate results; ARA is not a quick fix.

Adherence to a high-carbohydrate diet (60% energy) for 14-20 weeks significantly increases regional cerebral blood flow in the nucleus accumbens (reward) and hypothalamus (homeostasis) compared to a low-carbohydrate diet (20% energy), suggesting neural mechanisms that may impede weight-loss maintenance.

If you are trying to maintain weight loss, the type of carbohydrates you eat matters for your brain's reward system. A diet high in carbohydrates (60% of calories) was shown to increase blood flow to the brain's reward and hunger centers compared to a low-carb diet (20% of calories). This neural activation may make it harder to stick to your diet long-term, even if you are eating the same number of calories. Consider reducing carbohydrate intake to lower levels to potentially dampen these reward-driven hunger signals.

Whole-room indirect calorimetry provides highly reliable measurements of daily energy expenditure components (sleep, 24-hour, basal, and resting EE) with intraclass correlation coefficients exceeding 90%, and this reliability is maintained even after significant weight loss.

If you are designing a study on weight loss or metabolic adaptation, whole-room indirect calorimetry is a highly reliable tool for measuring energy expenditure. To maximize efficiency and reduce the number of participants needed, use at least two days of measurement in the calorimeter rather than one, as this significantly improves the precision of detecting changes in energy expenditure.

The efficacy of GLP-1RA combined with lifestyle modification is influenced by treatment duration, drug type (semaglutide/tirzepatide), dosing frequency (weekly), and geographic region (North America).

For the best weight loss results with GLP-1RAs, choose a weekly formulation (like semaglutide or tirzepatide) if possible, maintain the treatment for at least a year, and ensure your lifestyle intervention is consistent. Regional factors may also play a role in outcomes.

A moderate increase in protein intake (from ~0.8 to ~1.2 g/kg/day) provides a small additional improvement in functional capacity (specifically longer walk tests) but does not improve muscle strength or lean mass quality in postmenopausal women following resistance exercise.

If you are a postmenopausal woman starting resistance training, aim for about 1.2 grams of protein per kilogram of body weight daily. This moderate increase over the standard recommendation (0.8 g/kg) may help you walk faster and perform daily tasks better, but it will not necessarily make your muscles stronger or larger compared to eating the standard amount. Focus on consistent resistance training.

In older adults with type 2 diabetes, weight cycling and weight regain following intentional weight loss are associated with significantly worse physical function (gait speed, expanded physical performance battery) in women and weaker grip strength in men compared to maintaining or continuing weight loss.

If you have type 2 diabetes, keeping the weight you lose is just as important as losing it. Regaining weight or constantly going up and down (cycling) can weaken your grip and slow your walking speed, especially for women. Focus on strategies to maintain your weight loss to protect your physical function and independence as you age.

Discontinuation rates for weight-reducing (WR) diabetes-specific medications are nearly twice as high as those for weight-inducing (WI) medications, indicating poor persistence with preferred therapies.

If you start a weight-reducing diabetes medication, be prepared for a higher chance of stopping it compared to older weight-gain drugs. This is common, so don't be discouraged. Talk to your doctor about managing side effects, starting with a lower dose, or switching to an oral formulation if injections are the issue. Persistence is key to seeing long-term benefits.

GLP-1 receptor agonists (GLP-1RAs) significantly reduce hepatic steatosis and improve metabolic markers in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), but they do not significantly improve liver fibrosis.

GLP-1 medications like semaglutide and tirzepatide are effective at reducing liver fat and improving metabolic health in people with fatty liver disease. However, they do not currently appear to reverse liver scarring (fibrosis). While they offer significant benefits for steatosis and weight loss, patients should be aware of common gastrointestinal side effects and the current limitation regarding fibrosis reversal.